Literature DB >> 24719246

Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy.

Arzu Akcay1, Zafer Salcioglu, Kazim Oztarhan, Deniz Tugcu, Gonul Aydogan, Nuray Aktay Ayaz, Helen Bornaun, Hulya Sayilan Sen, Ferhan Akici, Burhan Akdana.   

Abstract

The aim of the study is to assess the relationship between T2* magnetic resonance imaging (MRI) values and age, serum ferritin level, left ventricular ejection fraction (LVEF), splenectomy status, and to identify appropriate modifications to chelation therapy based on T2* MRI results of children with thalassaemia major. Sixty-four patients with thalassaemia major (37 girls/27 boys) older than 8 years of age were enrolled in the study. Based on the first T2* MRI, the patients' myocardial iron depositions were classified into three groups: T2* MRI <10 ms (high risk group), T2* MRI 10-20 ms (medium-risk group) and T2* MRI >20 ms (low-risk group). There was no significant relationship between T2* MRI value and ages, serum ferritin levels and splenectomy status of thalassaemia major patients. The mean LVEFs were 60, 75, and 72.5 % in the high-, medium-, and low-risk groups, respectively (P = 0.006). The mean cardiac iron concentrations calculated from the T2* MRI values were 4.96 ± 1.93, 1.65 ± 0.37, and 0.81 ± 0.27 mg/g in the high-, medium-, and low-risk groups, respectively. Chelation therapies were re-designed in 24 (37.5 %) patients according to cardiac risk as assessed by cardiac T2* MRI. In conclusion, until recently, T2* MRI has been employed to demonstrate cardiac siderosis without a direct relationship with the markers used in follow-up of patients with thalassaemia. However, modifications of chelation therapies could reliably be planned according to severity of iron load displayed by T2* MRI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24719246     DOI: 10.1007/s12185-014-1575-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease.

Authors:  John C Wood; J Michael Tyszka; Susan Carson; Marvin D Nelson; Thomas D Coates
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

2.  Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

3.  Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

Authors:  Annita Kolnagou; George J Kontoghiorghes
Journal:  Hemoglobin       Date:  2006       Impact factor: 0.849

4.  Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

Authors:  Emanuele Angelucci; Giovanni Barosi; Clara Camaschella; Maria Domenica Cappellini; Mario Cazzola; Renzo Galanello; Monia Marchetti; Antonio Piga; Sante Tura
Journal:  Haematologica       Date:  2008-04-15       Impact factor: 9.941

5.  Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Amal El-Beshlawy; Lee Lee Chan; Yesim Aydinok; Mohsen Saleh Elalfy; Pranee Sutcharitchan; Chi-Kong Li; Hishamshah Ibrahim; Vip Viprakasit; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Blood       Date:  2009-12-08       Impact factor: 22.113

Review 6.  T2* magnetic resonance and myocardial iron in thalassemia.

Authors:  Dudley J Pennell
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

7.  Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis.

Authors:  Yesim Aydinok; Selen Bayraktaroglu; Dilek Yildiz; Hudaver Alper
Journal:  J Pediatr Hematol Oncol       Date:  2011-07       Impact factor: 1.289

8.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

9.  How I treat transfusional iron overload.

Authors:  A Victor Hoffbrand; Ali Taher; Maria Domenica Cappellini
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

10.  A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload.

Authors:  Mark Westwood; Lisa J Anderson; David N Firmin; Peter D Gatehouse; Clare C Charrier; Beatrix Wonke; Dudley J Pennell
Journal:  J Magn Reson Imaging       Date:  2003-07       Impact factor: 4.813

View more
  1 in total

1.  Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.

Authors:  Zeynep Karakas; Yasin Yilmaz; Zuhal Bayramoglu; Serap Karaman; Selime Aydogdu; Ayse Ozkan Karagenc; Deniz Tugcu; Memduh Dursun
Journal:  Radiol Med       Date:  2018-04-16       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.